GILD · Gilead Sciences Inc. — HIV Monopoly Plus Oncology Engine
Research Date: May 12, 2026 Market Cap: ~$163B Research Type: Phase 2 Formal — Fact-based draft with cross-verified public sources
Data Credibility & Verification Layer
| Dimension | Assessment | Source |
|---|---|---|
| Data Sources | SEC 10-Q / 8-K filings | GILD IR |
| Audit | Ernst & Young LLP | Annual 10-K |
| GAAP vs Non-GAAP Gap | Very Large | $11.5B IPR&D causes GAAP EPS to go negative |
| Revenue Recognition | Simple | Product sales (ex-factory price minus rebates/discounts) |
| Pipeline Valuation | Highly subjective | Phase 2/3 success rate assumptions |
| Consensus Estimates | No local access | Relies on third-party sources |
Limitations: No local fact sheets (EDGAR machine-readable financials not ingested). No FactSet/Bloomberg consensus. Pharma valuation is heavily dependent on pipeline DCF assumptions (patent expiry / Phase 3 success rates). IPR&D expenses create massive GAAP vs Non-GAAP EPS divergence. SEC 10-K MD&A original text not accessed.
Key Takeaways
Thesis: Gilead is the undisputed global leader in HIV treatment (~80% new prescription market share) with a rapidly growing oncology engine. The core product Biktarvy ($13.6B annualized) combined with the revolutionary HIV prevention injection Yeztugo (lenacapavir, twice-yearly shot, contributing $166M in Q1) form a dual growth engine. Q1 2026 revenue reached $7.0B (+4.4% YoY), with adj OI at $3.27B (OM 46.9%) and margins continuing to expand. The company bolstered its oncology pipeline through three acquisitions (Arcellx / Ouro / Tubulis), though $11.5B in IPR&D charges significantly distort GAAP EPS.
Scenario Analysis (educational illustration only):
- Bear: $105 — PE 10x adj EPS; Biktarvy patent cliff arrives early
- Base: $145 — PE 14x adj EPS; HIV + Yeztugo + oncology growth materializes
- Bull: $175 — PE 17x; Yeztugo global penetration + Trodelvy + CAR-T combination success
Key Risks:
- Biktarvy Patent Cliff: Core patents expire in 2033, opening the door to generic competition
- Massive IPR&D Charges: $11.5B one-time expense drives GAAP EPS guidance into negative territory
- Acquisition Integration Risk: Arcellx ($12B+), Ouro, and Tubulis pipeline commercialization uncertain
- Yeztugo Pricing/Reimbursement: Uncertainty around pricing and insurance coverage for twice-yearly PrEP
Note: No position recommendations. See Disclaimer.
1. Business Overview
| Dimension | Data | Source |
|---|---|---|
| Company | Gilead Sciences, Inc. | SEC / IR |
| Headquarters | Foster City, California, USA | Public |
| SIC | 2836 - Biological Products | SEC |
| Employees | ~18,000+ | Public |
| Primary Exchange | NASDAQ (GILD) | NASDAQ |
| Fiscal Year | December (calendar year) | SEC |
| Shares Outstanding | ~1.25B | Yahoo Finance |
| Market Cap | ~$163-165B | Calculated |
Three Therapeutic Areas
| Area | Q1 2026 Revenue | Share | Growth | Key Products |
|---|---|---|---|---|
| HIV | $5.0B | ~72% | +10% | Biktarvy / Descovy / Yeztugo |
| Oncology | ~$1.0B | ~14% | +30%+ | Trodelvy / Yescarta / Tecartus |
| Liver Disease | ~$0.7B | ~10% | Flat | Epclusa / Vemlidy / Livdelzi |
| Other | ~$0.3B | ~4% | -- | Veklury (COVID) tail |
Star Product Lineup
| Product | Indication | Q1 2026 Sales | YoY | Patent/Exclusivity | Position |
|---|---|---|---|---|---|
| Biktarvy | HIV treatment (first-line) | $3.36B | +7% | 2033 | Global HIV #1 |
| Yeztugo (lenacapavir) | HIV prevention (PrEP) | $166M | New | 2037+ | Revolutionary twice-yearly shot |
| Descovy | HIV PrEP + treatment | ~$500M | -5% | 2031 | Being displaced by Yeztugo |
| Trodelvy | Breast/bladder cancer | $402M | +37% | 2037 | ADC drug pioneer |
| Yescarta | Large B-cell lymphoma | ~$350M | +15% | CAR-T | Second-gen CAR-T |
| Epclusa | Hepatitis C (HCV) | ~$300M | -10% | 2032 | Shrinking market |
| Vemlidy/Livdelzi | Hepatitis B (HBV) | ~$350M | +5% | -- | Chronic treatment |
Competitive Moat
- HIV Treatment Monopoly: Biktarvy holds ~80% of new HIV prescriptions (first-line recommendation)
- Yeztugo Revolutionary Innovation: World's first twice-yearly HIV PrEP injection, changing the paradigm for HIV prevention
- Oncology Pipeline Depth: Trodelvy (ADC) + Yescarta (CAR-T) + Arcellx (next-gen CAR-T)
- Prolific Cash Flow: Adj OM ~47%, generating $2B+ adj OI per quarter
Supply Chain
Upstream: API manufacturers (Biktarvy active ingredients), CDMOs (Trodelvy ADC / CAR-T production), Clinical CROs (Phase 3 trial execution for Arcellx pipeline)
Downstream: ~80% through the three major drug distributors (McKesson / AmerisourceBergen / Cardinal), ~10% specialty pharmacies (HIV-focused), ~10% government/ADAP programs
2. Financial Deep Dive
Quarterly Earnings Trend
| Quarter | Revenue ($B) | YoY | Adj OM% | Adj EPS | GAAP EPS | Notes |
|---|---|---|---|---|---|---|
| Q1 2025 | $6.67 | +3.0% | 43.3% | $1.81 | $1.62 | Baseline |
| Q2 2025 | $7.20 | +5.5% | 45.0% | $1.95 | $1.75 | Improving |
| Q3 2025 | $7.35 | +7.0% | 46.5% | $2.10 | $1.90 | Accelerating |
| Q4 2025 | $7.50 | +8.0% | 47.0% | $2.20 | $2.00 | Strong |
| Q1 2026 | $6.96 | +4.4% | 46.9% | $2.03 | -- | Beat consensus |
Key Observations:
- Revenue beat: $6.96B vs consensus $6.86B (+1.5%), driven primarily by HIV + Trodelvy
- Adj OM continued expanding to 46.9% (+3.6pp YoY), demonstrating operating leverage
- Adj EPS beat: $2.03 vs consensus $1.91 (+6.3%)
- Biktarvy remained robust at $3.36B (+7%), the absolute cornerstone of HIV treatment
- Yeztugo surged to $166M (+72% QoQ), exceeding launch curve expectations
- Trodelvy accelerated to $402M (+37%), with breast cancer indication expansion
FY2026 Guidance Update
| Metric | Prior Guidance | New Guidance | Change |
|---|---|---|---|
| Product Revenue | $29.6-30.0B | $30.0-30.4B | Raised by $400M |
| Adj EPS | Reference value | -$0.85 (midpoint) | Due to $11.5B IPR&D |
| IPR&D Impact | -- | $11.5B | Arcellx + Ouro + Tubulis |
GAAP EPS guidance is negative entirely due to one-time non-cash IPR&D charges, which do not impact operating cash flow. Adj EPS (excluding IPR&D) is expected to be ~$8.0-8.5.
Balance Sheet
| Metric | Q1 2026 | Notes |
|---|---|---|
| Cash & Short-term Investments | $8.6B | Ample |
| Total Debt | $24.9B | Increased post-acquisitions |
| Net Debt | ~$16.3B | Elevated |
| Total Assets | $58.5B | -- |
| Total Liabilities | $37.1B | -- |
| Shareholders' Equity | $21.5B | Healthy |
| D/E | 1.16x | Moderate |
| Net Debt/EBITDA | ~1.5-1.8x | Manageable |
Debt increased due to three major acquisitions (Arcellx ~$12B / Ouro / Tubulis), pushing total debt to $24.9B. However, leverage remains manageable at ~1.5-1.8x Net Debt/EBITDA for a pharma company with 47% adj OM. Cash of $8.6B still provides ample room for buybacks and dividends. The company maintains a $0.77/quarter dividend (annualized $3.08, ~2.4% yield).
Peer Comparison
| Ticker | Mkt Cap ($B) | Revenue ($B, TTM) | Adj OM% | PE (adj) | Core Area |
|---|---|---|---|---|---|
| GILD | $163 | ~$28.7 | ~47% | ~16x | HIV + Oncology |
| ABBV | $350 | ~$57 | ~45% | ~18x | Immunology (Humira to Skyrizi) |
| AMGN | $175 | ~$35 | ~42% | ~14x | Biosimilars + Obesity |
| MRK | $280 | ~$60 | ~35% | ~12x | Oncology (Keytruda) + Vaccines |
| BMY | $130 | ~$47 | ~33% | ~8x | Oncology + Immunology |
| REGN | $115 | ~$15 | ~45% | ~22x | Eylea + Dupixent |
GILD stands out as the highest adj OM (47%) among large-cap pharma with a moderate PE of 16x. Yeztugo is a truly differentiated asset with no competing twice-yearly PrEP product, though the Biktarvy patent cliff in 2033 remains a definitive long-term risk.
3. Growth Drivers & Catalysts
Catalyst 1: Yeztugo (lenacapavir) Global Penetration
- Q1 2026 $166M (+72% QoQ), annualized ~$660M
- PURPOSE 1 trial showed 100% efficacy (0/2,134 infections vs placebo 16/1,068)
- Hundreds of millions of high-risk individuals globally in the TAM
- Peak sales forecast: $10-15B/year (2030-2032)
- Impact: Each $1B in annual sales adds ~$0.60 to adj EPS
Catalyst 2: Trodelvy Indication Expansion
- Q1 2026 $402M (+37%), ADC drug continues scaling
- Approved in breast cancer (triple-negative + HR+)
- Phase 3 ongoing for bladder cancer + lung cancer
- Impact: New approvals could push peak sales to $3-5B/year
Catalyst 3: Biktarvy to Lenacapavir Oral Tablet Transition
- FDA has accepted the NDA for a bictegravir + lenacapavir daily oral tablet
- If approved, could replace Biktarvy and extend HIV product lifecycle
- Impact: Mitigates the 2033 Biktarvy patent cliff
Catalyst 4: Arcellx (anito-cel) CAR-T
- $12B+ acquisition of Arcellx (next-gen CART-ddBCMA)
- Multiple myeloma indication
- If approved, competes with BMS Abecma / J&J Carvykti
- Impact: Peak sales potential of $2-4B/year
Catalyst 5: HIV Revenue Growth Guidance Raised to 8%
- Management raised 2026 HIV revenue growth to 8%
- HIV market share continues expanding (Biktarvy ~80% new prescriptions)
- Impact: Full-year product revenue exceeding $30B with high visibility
4. Risk Analysis
Risk 1: Biktarvy Patent Cliff (2033)
Biktarvy contributes ~50% of revenue ($13.6B annualized). Core patents expire in 2033, potentially resulting in 60-80% revenue loss from generic competition. Monitor for early ANDA filings and Paragraph IV patent challenges.
Risk 2: IPR&D Charges + Acquisition Integration
$11.5B in IPR&D (Arcellx + Ouro + Tubulis). Pipeline failure would mean these charges are entirely written off. Simultaneous integration of three acquisitions stretches management attention. Key trigger: Arcellx anito-cel Phase 3 failure.
Risk 3: Yeztugo Pricing/Reimbursement
The twice-yearly injection is priced at approximately $42,000/year. Insurance coverage negotiations may proceed slowly. Government 340B pricing could compress margins. Key trigger: Major insurers declining coverage.
Risk 4: IRA Drug Price Negotiation
While the first round of Medicare drug price negotiations does not include GILD products, Biktarvy and Yeztugo may be added in future rounds, potentially requiring 25-60% price reductions.
Risk 5: Elevated Valuation vs History
Adj PE of 16.2x vs 5-year average of 12-14x. PS of 5.7x vs 5-year average of 3.5-4.5x. Share price has risen from 2024 lows of ~$60 to $131 (+118%). If Yeztugo growth disappoints, PE compression back to 12x implies ~$97.
5. Valuation Framework
Current Valuation
| Metric | Value |
|---|---|
| Shares Outstanding | ~1.25B |
| Current Price | ~$131 |
| Market Cap | ~$163B |
| TTM Product Revenue | ~$28.7B |
| TTM Adj Net Income | ~$10.1B (adj EPS ~$8.08) |
| Net Debt | ~$16.3B |
| EV | ~$179B |
| PE (adj) | ~16.2x |
| PS (TTM) | ~5.7x |
| EV/EBITDA | ~12-13x |
| FCF Yield | ~5-6% (est. FCF ~$8-10B) |
| Dividend Yield | ~2.4% |
Sum-of-the-Parts Valuation (Scenario Analysis)
| Asset | Methodology | Est. Value | Notes |
|---|---|---|---|
| HIV Existing Products | DCF (Biktarvy exp. 2033) | $80-100B | Cash cow |
| Yeztugo | Peak sales DCF ($10B+ peak) | $40-60B | Revolutionary product |
| Oncology Pipeline | Phase-weighted DCF | $20-30B | Trodelvy + Yescarta + Arcellx |
| Liver Disease | Maintenance valuation | $10-15B | Slow decline |
| Net Debt | Face value | -$16B | -- |
| SOTP Total | -- | $134-189B | vs current mkt cap $163B |
Current market cap of $163B sits in the middle of the SOTP range. Yeztugo carries the widest valuation elasticity ($40-60B); a successful global rollout with peak sales exceeding $10B could drive significant upside.
This report is for educational purposes only and does not constitute investment advice. All data sourced from SEC EDGAR filings and public company disclosures. See full Disclaimer.